《2023年乳腺癌最新进展 第1部分 - 早期乳腺癌》
Update Breast Cancer 2023 Part 1 - Early Stage Breast Cancer.
作者信息
Hartkopf Andreas D, Fehm Tanja N, Welslau Manfred, Müller Volkmar, Schütz Florian, Fasching Peter A, Janni Wolfgang, Witzel Isabell, Thomssen Christoph, Beierlein Milena, Belleville Erik, Untch Michael, Thill Marc, Tesch Hans, Ditsch Nina, Lux Michael P, Aktas Bahriye, Banys-Paluchowski Maggie, Kolberg-Liedtke Cornelia, Wöckel Achim, Kolberg Hans-Christian, Harbeck Nadia, Stickeler Elmar, Bartsch Rupert, Schneeweiss Andreas, Ettl Johannes, Würstlein Rachel, Krug David, Taran Florin-Andrei, Lüftner Diana
机构信息
Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany.
Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany.
出版信息
Geburtshilfe Frauenheilkd. 2023 Jun 6;83(6):653-663. doi: 10.1055/a-2074-0551. eCollection 2023 Jun.
With abemaciclib (monarchE study) and olaparib (OlympiA study) gaining approval in the adjuvant treatment setting, a significant change in the standard of care for patients with early stage breast cancer has been established for some time now. Accordingly, some diverse developments are slowly being transferred from the metastatic to the adjuvant treatment setting. Recently, there have also been positive reports of the NATALEE study. Other clinical studies are currently investigating substances that are already established in the metastatic setting. These include, for example, the DESTINY Breast05 study with trastuzumab deruxtecan and the SASCIA study with sacituzumab govitecan. In this review paper, we summarize and place in context the latest developments over the past months.
随着阿贝西利（monarchE研究）和奥拉帕利（OlympiA研究）在辅助治疗领域获得批准，早期乳腺癌患者的标准治疗方案在一段时间以来已经发生了重大变化。因此，一些不同的进展正慢慢地从转移性治疗领域转移到辅助治疗领域。最近，NATALEE研究也有了积极的报告。其他临床研究目前正在研究已在转移性治疗领域确立的药物。例如，这些研究包括使用曲妥珠单抗德鲁昔康的DESTINY Breast05研究和使用戈沙妥珠单抗的SASCIA研究。在这篇综述文章中，我们总结并梳理了过去几个月的最新进展。
Zotero 插件